Incidence of Dual AV Node Physiology Following Termination of AV Nodal Reentrant Tachycardia by Adenosine-5'-Triphosphate: A Comparison with Drug Administration in Sinus Rhythm by Belhassen, Bernard et al.
 
www.ipej.org 3
Original Article
Incidence of Dual AV Node Physiology Following 
Termination of AV Nodal Reentrant Tachycardia by 
Adenosine-5'-Triphosphate: A Comparison with Drug 
Administration in Sinus Rhythm
Bernard Belhassen, MD; Roman Fish, MD; Sami Viskin, MD; Aharon Glick, MD; Michael 
Glikson, MD; Michael Eldar, MD                                                                                 
Departments of Cardiology, Tel-Aviv Sourasky and Chaim Sheba Medical Centers, and Tel-
Aviv University, Sackler School of Medicine, Tel-Aviv, Israel                                          
Address for correspondence: Dr. Bernard Belhassen, MD, Department of Cardiology, Tel-Aviv 
Sourasky   Medical   Center,   Weizman   Street   6,   Tel-Aviv   64239,   Israel.
E-mail:  bblhass@tasmc.health.gov.il                                                                                                      
Abstract
            Administration   of   adenosine   triphosphate   (ATP)   in   sinus   rhythm   identifies   dual 
atrioventricular node physiology (DAVNP) in 75% of patients with inducible slow / fast AV 
nodal reentrant tachycardia (AVNRT). The incidence of DAVNP following termination of 
AVNRT with ATP is unknown. Incremental doses of ATP (10-60mg) were administered, first in 
sinus rhythm and then during tachycardia induced at electrophysiologic study, to 84 patients 
with inducible AVNRT and to 18 control patients with inducible AV reentrant tachycardia 
(AVRT) and no electrophysiologic evidence of DAVNP. Study end-points were the occurrence 
of DAVNP or > 2nd degree AV block following administration of ATP in sinus rhythm and 
tachycardia termination following administration of ATP during tachycardia. Of the 82 patients 
with AVNRT who completed the study, 62 (75.6%) exhibited DAVNP following administration 
of 17.1 + 9.4 mg ATP in sinus rhythm, while 30 (36.5%) exhibited DAVNP at the termination of 
AVNRT following administration of 10.6 + 2.4 mg ATP. The occurrence of DAVNP following 
the administration of 10 mg ATP in sinus rhythm.was a good predictor (62%) of its occurrence 
after termination of AVNRT with ATP. The dose of ATP had a strong correlation between the 
presence of DAVNP following AVNRT termination and the ATP doses needed for tachycardia 
termination. Of the 18 control patients, none had DAVNP at ATP test during sinus rhythm but 1 
(5.5%) showed slight (60 msec) PR jump after termination of AVRT with ATP. In conclusion, 
DAVNP is present in a relatively high proportion (36.5%) of patients following termination of 
AVNRT with ATP but is much less frequent (5.5%) in control patients. Thus, findings at 
termination of tachycardia by ATP may be useful in the noninvasive diagnosis of the mechanism 
of a paroxysmal supraventricular tachycardia.                                                             
Key   words:  Adenosine   triphosphate;   AV   nodal   reentrant   tachycardia;   dual   AV   node 
physiology.
Introduction
             Atrioventricular   nodal   reentrant   tachycardia   (AVNRT)   is   the   most   frequently 
encountered type of regular, paroxysmal supraventricular tachycardia in clinical practice. The 
typical form, observed in >95%  of  cases  of  AVNRT,  is  due  to  a  reentrant  mechanism  that 
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involves a slow pathway in the antegrade direction and a fast pathway in the retrograde 
direction. Adenosine-5'-triphosphate (ATP) is almost always effective for terminating AVNRT 
usually by blocking the antegrade slow pathway 1. Besides this well known therapeutic effect, 
ATP has been found to be useful in the noninvasive diagnosis of dual AV node physiology 
(DAVNP). We previously showed that 75% of patients with inducible sustained typical AVNRT 
exhibited electrocardiographic signs suggesting DAVNP following administration of ATP in 
sinus rhythm 2. Since DAVNP following administration of ATP in sinus rhythm occurs at a time 
span very close to that at which ATP terminates AVNRT  1,2, one may speculate that this 
phenomenon should be a relatively frequent finding upon termination of AVNRT with 
adenosine compounds. However, despite a wide use of adenosine compounds in the acute 
management of AVNRT, there has been no previous study of this phenomenon. The present 
work was undertaken in order to: a) assess the incidence of DAVNP following termination of 
AVNRT with ATP and compare it with that observed following administration of ATP in sinus 
rhythm; b) compare the characteristics of DAVNP, the time of onset and the doses of ATP 
required for the occurrence of this phenomenon in the two settings; c) compare the incidence of 
DAVNP following termination of tachycardia in patients with inducible AVNRT and those with 
inducible AV reentrant tachycardia (AVRT) involving a concealed accessory pathway but 
without electrophysiologic evidence for DAVNP.
Methods
Patient Selection: The study group consisted of consecutive patients in whom the effects of the 
intravenous administration of ATP were tested both in sinus rhythm and during sustained (> 1 
min) slow / fast AVNRT induced at electrophysiologic study. All patients were evaluated in the 
absence of antiarrhythmic drug therapy and patients in whom isoproterenol was required to 
induce AVNRT were excluded. Most patients were included in another study dealing with the 
use of a simplified ATP test for the noninvasive diagnosis of dual AV nodal physiology and the 
assessment of the results of slow pathway ablation in patients with AVNRT 3.                              
            The control group consisted of patients who had inducible sustained AVRT involving a 
concealed accessory pathway and in whom the effects of the intravenous administration of ATP 
were tested both in sinus rhythm and during sustained (> 1 min) AVRT. Patients were excluded 
if they had electrophysiologic evidence of DAVNP defined as sudden prolongation of AH by > 
50 msec when shortening the cycle length of atrial pacing or the coupling interval of the atrial 
extrastimulus by 10 msec. Most of these patients were part of a larger study that assessed the use 
of ATP in the noninvasive diagnosis of concealed accessory pathway 4.                                 
            None of the patients participating in the study had a history of asthma (a contraindication 
to ATP administration), or was treated with drugs known to interfere with ATP metabolism 
(aminophylline, dipyridamole, benzodiazepines).                                                               
ATP Test: This protocol was approved by our Ethical Committee and all patients gave informed 
consent. The effects of ATP on AV nodal conduction in sinus rhythm were evaluated before the 
introduction of any electrode catheter into the cardiac chambers in order to avoid any catheter-
induced arrhythmia or trauma to the fast or slow pathways  5. After positionning electrode 
catheters in the heart, a diagnostic electrophysiologic study was performed according to a 
previously described protocol 1. ATP was then given after a sustained (> 1 min) slow / fast 
AVNRT (study group) or AVRT (control group) was induced. ATP (Striadyne, Wyeth 
Laboratories, France) was injected through a right antecubital vein as a rapid bolus followed by 
a 20 ml flush of normal saline. The initial dose of ATP was 10 mg. Repeated doses (with 10 mg 
increments) were given at 1-2 minutes intervals until a study end-point was achieved. The study 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(1): 3-9 (2003)Bernard Belhassen, Roman Fish, Sami Viskin, Aharon Glick, Michael Glikson,           5 
Michael Eldar, “Incidence of Dual AV Node Physiology Following Termination of AV Nodal 
Reentrant   Tachycardia   by   Adenosine-5'-Triphosphate:   A   Comparison   with   Drug 
Administration in Sinus Rhythm” 
end-points following administration of ATP in sinus rhythm were: a) ECG signs of DAVNP (see 
below);   b)   Second   degree   or   third   degree   AV   block.   The   study   end-point   following 
administration of ATP during AVNRT or AVRT was tachycardia termination. The study was 
discontinued if severe clinical intolerance or bradycardia causing >3 sec pause occurred or when 
a maximal dose of 60 mg ATP was given. The following parameters were recorded in each 
patient: a) the dose of ATP required for achieving any study end-point; b) the time from 
injection of ATP to the occurrence of any study end-point; and c) the maximal number of 
conducted beats over the slow pathway in patients who exhibited DAVNP following ATP 
administration.
Definitions of Dual AV Node Physiology by ATP Test: DAVNP was considered to be present 
when at least one of the following events occurred following ATP injection: 1) PR interval 
increased or decreased by >50 ms in 2 consecutive sinus beats; 2) an AV nodal echo beat was 
observed; 3) AVNRT developed. All 3 criteria were solely based on the analysis of simultaneous 
12-lead surface electrocardiogram. Single AV nodal echoes are often difficult to discern without 
the aid of intracardiac recordings. However, AV nodal echoes would be expected to reset the 
sinus activity. Therefore, AV nodal echos were considered to be present when, following a sinus 
complex conducted with an increased PR interval: a) a >70% increment in P-P interval was 
observed or b) retrograde P waves were seen at the end of the QRS complex. We previously 
found a good correlation between these electrocardiographic criteria and the diagnosis of 
DAVNP using intracardiac recordings  2.                                                                     
Statistics: Data were expressed as mean + SD. Statistical comparison of data was performed 
using the t-test for paired or unpaired samples or the chi-square test as appropriate. A value of 
p<0.05 was considered statistically significant.                                               
Results
Study Group:  The effects of the intravenous administration of ATP were assessed in sinus 
rhythm and during AVNRT in 84 patients. Two (2%) patients were excluded from further 
analysis: 1 because he did not reach a study end-point despite administration of 60 mg ATP in 
sinus rhythm, and 1 because he withdrew his consent to participate in the study after receiving 
10 mg of ATP in sinus rhythm. The remaining 82 patients [53 females and 29 males (age 46 + 
15 years)] reached a study end-point following administration of ATP in sinus rhythm and 
AVNRT and constituted the study group.                                                                                 
Effects of ATP in Sinus Rhythm: Of the 82 study patients, 62 (75.6%) patients exhibited signs of 
DAVNP following administration of 17.1 + 9.4 (range 10 - 40) mg ATP. DAVNP occurred after 
administration of 10 mg ATP in 34 (55%) patients, after 20 mg in 22 (35%) patients and after > 
30 mg in 6 (10%) patients (Fig 1). This occurred 7 to 24 sec (mean 15.3 + 3.3) following the 
ATP bolus. The number of conducted beats over the slow pathway ranged from 1 to 16 (mean 
3.8 + 3). AV nodal echoes (range 1 to 4, mean 1.5 + 0.9) following ATP injection were observed 
in 14 (17%) study patients. None of the study patients developed AVNRT. The remaining 20 
(24.4%) patients developed > second degree AV block without ECG signs of DAVNP following 
administration of 20.6 + 10.9 (range 10 - 60) mg ATP.
Effects of ATP during AVNRT: AVNRT was terminated by ATP in all 82 (100%) study patients. 
This occurred 6 to 25 (mean 16.3 + 4.9) sec following the ATP bolus. The doses of ATP that 
terminated the tachycardia were 10 mg and 20 mg in 77 and 5 patients, respectively (mean 10.6 
+ 2.4 mg). In all patients, tachycardia terminated due to antegrade block in the slow pathway. 
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DAVNP at the termination of AVNRT was observed in 30 (36.5%) patients (Table 1) . This 
occurred 6 to 37 (mean 18.1+ 6.8) sec following the ATP bolus. The doses of ATP that resulted 
in appearance of DAVNP in the 30 patients were 10 mg and 20 mg in 29 and 1 patients, 
respectively (mean 10.3 + 1.8 mg). The number of conducted beats over the slow pathway 
ranged from 1 to 12 (mean 3.5 + 2.9). Second or higher degree of AV block was also observed 
in 13 patients who exhibited ECG signs of DAVNP.                                                   
Figure 1: Presence of dual AV node physiology both during administration of ATP in 
sinus   rhythm   and   during   tachycardia.                                                
Panel A.  Administration of 10 mg ATP in sinus rhythm results 14 sec later in the 
occurrence of dual AV node physiology (PR jump by 80 msec on the 2nd beat); the 14 
next sinus beats are conducted over the slow pathway and conduction over the fast 
pathway resumes afterwards (16th beat).                                                         
Panel B. Administration of 10 mg ATP during slow / fast AV nodal reentry tachycardia 
terminates the tachycardia after 16 sec. Six sinus beats conducting over the slow pathway 
are observed following tachycardia termination. The apparent irregularity of the sinus 
beats is best explained by the post-compensatory pause resulting from single AV nodal 
echos (arrows) that follow conduction over the slow pathway.
Overall Comparison of the Effects of ATP during Sinus Rhythm and AVNRT (Table 1): DAVNP 
after termination of AVNRT was more frequently observed in patients who exhibited DAVNP 
in sinus rhythm (26 of 62, 42%) than in those who did not (4 of 20, 20%) but the difference did 
not reach statistical significance (p=0.08).                                                                 
            In the whole group of patients, the dose of ATP necessary for demonstrating DAVNP in 
sinus rhythm (17.1  +  9.4 mg, n=62) was greater than that required to show DAVNP after 
conversion of AVNRT (10.6  +  2.4 mg, n=30) (p <0.001). However, the time of onset of 
DAVNP in these 2 groups was similar (15.3 + 3.3 sec vs 18.1 + 6.8 sec, p=NS). Also, the 
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number of conducted beats over the slow pathway following ATP administration was not 
statistically different in the 2 settings (3.8 + 3, n=62 vs. 3.5 + 2.9, n=30, p=NS). Among the 26 
patients who exhibited DAVNP both in sinus rhythm and after termination of AVNRT, the 
doses of ATP required were 12.7 + 6 mg and 10.4 + 2 mg, respectively (p<0.05). The time of 
occurrence of DAVNP was shorter after ATP injection in sinus rhythm (14.7 + 3.3 sec vs 19.3 + 
6.9 sec p<0.05); however, the number of conducted beats over the slow pathway following ATP 
administration was not statistically different in the 2 settings (5.1 + 3.5 vs 3.7 + 3.0, p=0.07). 
Table 1. Effects of ATP in the Patient Study Group (n=82)
ATP   =   adenosine   triphosphate;   AVNRT   =   atrioventricular   nodal   reentry 
tachycardia;   DAVNP = dual atrioventricular node physiology; NS = non 
significant; s = seconds; SP = slow pathway;  SR = sinus rhythm.
Comparison of the Effects of ATP during Sinus Rhythm and AVNRT in Respect to ATP dosage: 
There was a strong correlation between the ATP dose needed to demonstrate DAVNP in sinus 
rhythm and the odds for demonstrating DAVNP following AVNRT termination: 62% (21/34) of 
the patients who exhibited DAVNP following administration of 10 mg ATP in sinus rhythm, 
exhibited DAVNP following termination of AVNRT. In contrast, only 18% (5/28) of the 
patients who required > 20 mg ATP for demonstrating DAVNP in sinus rhythm, subsequently 
exhibited   DAVNP   upon   termination   of   AVNRT   with   any   ATP   dose   (p<0.0005).
Control Group: This group included 18 patients [13 females and 5 males (age 30 + 14 years)] 
who had AVRT and no electrophysiologic evidence for DAVNP. Administration of ATP (15.6 + 
7.4 mg) resulted in > second degree AV block without DAVNP in all patients. A mean dose of 
ATP (10.7 + 2.7 mg) terminated AVRT in all patients after 16 + 5 sec. A slight jump (+ 60msec) 
in PR interval was noted on 1 beat after tachycardia termination in only 1(5.5%) of the 18 
patients.  
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Discussion
Main Findings: The present study shows that administration of ATP in sinus rhythm reveals the 
presence of DAVNP in 75.6% of patients with inducible sustained slow / fast AVNRT and in 
none of the control patients with no electrophysiologic evidence of DAVNP. These results are 
consistent with those found in our pilot study using ATP (2) and by others using adenosine 6. 
The new finding is the relatively high incidence of DAVNP (36.5%) upon termination of 
AVNRT with ATP contrasting with its rarity (5.5%) in the control group. In spite of the 
worldwide use of ATP and adenosine for the termination of AVNRT during the last 20 years, 
there has been no previous study or report of the occurrence of DAVNP following conversion of 
AVNRT with these compounds. Our results suggest that such a phenomenon is underestimated 
rather   than   rare.                                                                                
            This incidence rate of DAVNP upon termination of AVNRT with ATP seems even more 
remarkable if one takes into account that the study end-point following administration of ATP 
during AVNRT was tachycardia termination rather than exposure of DAVNP. Since doses of 
ATP required to achieve DAVNP after drug administration in sinus rhythm were higher than 
those required for termination of AVNRT, it is tempting to speculate that higher ATP doses 
during AVNRT might have resulted in a higher incidence of DAVNP after tachycardia 
termination.  
Mechanism of Dual AV Node Physiology after ATP Administration: As explained elsewhere 2 
administration of ATP in sinus rhythm reveals the presence of DAVNP, in most patients with 
slow / fast AVNRT, by blocking the antegrade fast pathway while antegrade conduction over the 
slow pathway persists. This is due to the fact that the antegrade fast pathway, which has a 
refractory period longer than that of the slow pathway, is more sensitive to ATP 2. Uncovering 
of DAVNP after termination of AVNRT with ATP probably results from a more complex 
mechanism. In order for DAVNP to occur in this circumstance, two conditions need to be 
fulfilled: 1. Antegrade conduction over the slow pathway should recover after the block that 
causes tachycardia termination; 2. The disparity between the antegrade refractory periods of the 
fast and slow pathways should still be present when tachycardia terminates. In addition, it 
should be pointed out that the electrophysiologic properties of the slow and fast pathways may 
also be influenced by neurally-mediated changes resulting from sudden termination of the 
tachycardia. For example, upon tachycardia termination, overshoot of the blood pressure occurs 
that triggers a vagal reflex through extracardiac baroreceptors 7. This in turn may markedly 
affect the refractory periods of both fast and slow pathways.                                   
Predictors of Occurrence of Dual AV Nodal Physiology after Termination of AVNRT with 
ATP: The occurrence of DAVNP following administration of ATP during AVNRT was more 
frequently observed in those patients who exhibited DAVNP following ATP administration in 
sinus rhythm than in those who did not. This difference, however, did not reach statistical 
significance. In contrast, the occurrence of DAVNP after termination of AVNRT with ATP best 
correlated (in 62% of patients) with its occurrence following the administration of 10 mg ATP in 
sinus   rhythm.                                                                                                  
Limitations:  The present study was performed during the course of an electrophysiologic 
procedure and therefore its results cannot be extrapolated to the clinical setting. When adenosine 
compounds are administered in the acute management of spontaneously occurring AVNRT, this 
is generally after several hours of sustained tachycardia compared to 1 min of tachycardia as in 
the present study. Sympathetic activation resulting from hypotension and stress may be more 
marked during spontaneous, long-lasting tachycardias than during short-lasting laboratory-
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induced arrhythmias.  Taking in account  that adenosine's  negative chronotropic effect  is 
enhanced in the setting of adrenergic stimulation 8, one may assume a similar behavior of AV 
nodal conduction. The consequences of adrenergic stimulation on adenosine-induced DAVNP 
are unknown. Further studies are required in order to assess the incidence of DAVNP following 
the   termination   of   AVNRT   by   adenosine   compounds   in   the   clinical   setting.  
Clinical Implications: Although the diagnosis of AVNRT is usually easy when a 12-lead ECG 
is available, the actual diagnosis may remain difficult in some instances. In addition, single strip 
electrocardiographic leads are frequently the only available data, especially when the patient is 
treated in a mobile care unit. According to our study, the presence of DAVNP following 
tachycardia termination by ATP would suggest that the mechanism of the tachycardia is actually 
AVNRT. Caution should prevail, however, since DAVNP can also be present in other types of 
PSVT. For example, we recently found that DAVNP could be suspected with ATP test in sinus 
rhythm in 7 (21%) of 33 patients with AVRT 4; however, when increasing the population size to 
57 patients, the incidence rate of DAVNP felt to 14%) (personal communication).                
Conclusions
           Termination   of   induced   slow   /   fast   AVNRT   with   ATP   is   followed   by 
electrocardiographic evidence of DAVNP in a relatively high proportion of patients. Such a 
finding   may   be   useful   in   the   noninvasive   diagnosis   of   the   mechanism   of   paroxysmal 
supraventricular   tachycardia.                                                                                  
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